Research programme: neurodegenerative disorders - Aegera
Latest Information Update: 12 Mar 2007
Price :
$50 *
At a glance
- Originator Aegera Therapeutics
- Class
- Mechanism of Action Apoptosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders; Parkinson's disease
Most Recent Events
- 12 Mar 2007 Discontinued - Preclinical for Neurological disorders in Canada (unspecified route)
- 12 Mar 2007 Discontinued - Preclinical for Parkinson's disease in Canada (Injection)
- 21 Oct 2002 Preclinical trials in Neurological disorders in Canada (unspecified route)